Prudence Ive

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

Diane V. Havlir, Michelle A. Kendall, Prudence Ive et al. · New England Journal of Medicine · 2011 · 538 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

David A. Cooper, Jayvant Heera, James Goodrich et al. · The Journal of Infectious Diseases · 2010 · 265 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

Ian Sanne, Catherine Orrell, Matthew P. Fox et al. · The Lancet · 2010 · 252 citations

Public Health, Advanced Practice Nursing, Clinical Pharmacy +13

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 249 citations

Medicine, Pharmacology, Pharmacotherapy +11

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study

Raph L Hamers, Rob Schuurman, Kim Sigaloff et al. · The Lancet Infectious Diseases · 2011 · 197 citations

Life Sciences, Infectious Diseases, Microbiology +17